Celanese Announces Grant Award to Develop Long-Acting, Refillable Drug Delivery Solution
August 24 2022 - 8:00AM
Business Wire
Celanese to conduct research, prototype
development and characterization of a refillable contraceptive
technology with award from the Bill & Melinda Gates
Foundation
Celanese Corporation (NYSE: CE), a global chemical and specialty
materials company, today announced receipt of a grant from the Bill
& Melinda Gates Foundation to produce and characterize a
working prototype for a refillable contraceptive implant. The
research and development will be conducted within the Celanese
Pharmaceutical Development and Feasibility Lab and the project is
expected to produce a functional prototype that meets all
established project parameters within an 18-month timeframe.
The development of a refillable contraceptive implant has the
potential to benefit women in low- and middle-income countries who
presently either do not have access to modern contraceptive options
or could benefit from the flexibility and control of the
contraception this product design affords. Through this grant,
Celanese will be providing critical research and development
activities intended to facilitate and accelerate access to
long-acting contraceptive options.
“We have a long history working in the area of women’s health
and are honored by the trust placed in our team through this grant
from the Gates Foundation,” said Laura Brand, vice president of the
Celanese medical and pharmaceutical business. “The project concept
is based on our VitalDose® drug delivery platform, a controlled
release technology with decades of commercial use in the US and
Europe. We are proud to be part of this opportunity to expand
access to solutions for women’s health to many more women
globally.”
Celanese offers cutting-edge medical and pharmaceutical material
solutions and expert development support to pharmaceutical and
medical device companies worldwide. With more than 40 years of
experience supporting key applications and the demanding
requirements of healthcare, Celanese continues to invest in this
area, including by finding new ways to deliver a sustained dose of
medication over time. The company’s expanding portfolio includes
solutions and technologies for applications across drug delivery,
medical devices, orthopedics, advanced surgical instruments and
connected devices.
For more information on Celanese VitalDose technology, visit
www.vitaldose.com.
About Celanese
Celanese Corporation is a global chemical leader in the
production of differentiated chemistry solutions and specialty
materials used in most major industries and consumer applications.
Our businesses use the full breadth of Celanese's global chemistry,
technology and commercial expertise to create value for our
customers, employees, shareholders and the corporation. As we
partner with our customers to solve their most critical business
needs, we strive to make a positive impact on our communities and
the world through The Celanese Foundation. Based in Dallas,
Celanese employs approximately 8,500 employees worldwide and had
2021 net sales of $8.5 billion. For more information about Celanese
Corporation and its product offerings, visit
www.celanese.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220824005302/en/
Investor Relations Brandon Ayache +1 972 443 8509
brandon.ayache@celanese.com
Media Relations – Global Brian Bianco +1 972 443 4400
media@celanese.com
Media Relations Europe (Germany) Petra Czugler +49 69
45009 1206 petra.czugler@celanese.com
Celanese (NYSE:CE)
Historical Stock Chart
From Apr 2024 to May 2024
Celanese (NYSE:CE)
Historical Stock Chart
From May 2023 to May 2024